Equal proportion of adult male and female homozygous for the 677C ? T mutation in the methylenetetrahydrofolate reductase polymorphism
about
Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal.Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects.Process map proposal for the validation of genomic biomarkers.Genetic variations and their influence on risk and treatment of venous thrombosis.The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics.Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics.Molecular biomarkers: a US FDA effort.Risk modeling strategies for pharmacogenetic studies.Genetics of ischemic stroke, stroke-related risk factors, stroke precursors and treatments.Disclosure of individual pharmacogenomic results in research projects: when and what kind of information to return to research participants.Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements.Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients.Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.Validation of warfarin pharmacogenetic algorithms in clinical practice.Prediction of optimal warfarin maintenance dose using advanced artificial neural networks.
P2860
Q27011524-AD8D3F26-5492-4322-B312-E44E4325C3E3Q33517162-236D2325-6D40-458D-A937-6B4A32B9BAF6Q34402967-2FA8E87E-B4D1-416B-84AA-86886B6AB867Q36555934-250FDC28-E5B2-45D9-BE31-29AF480BE90EQ37126654-87A5CC19-6435-4DDE-87DD-392CD8DA3BC7Q37247571-D1D7DF44-9E88-42B7-BD00-B172BDA961DCQ37264555-6FEC4AA7-0AED-4739-BE53-83115CD14980Q37734421-AABDC9C9-B028-4497-8B79-B4405A4A931AQ37859373-157688C3-BF91-4A3C-B517-88F5E83AFDF0Q37998525-A2D1B8B6-45CF-45B1-B8E8-13362FBF1972Q38097535-A8FAAB22-8BEA-40F5-85B1-2EEAC39BEF0BQ39862947-8C165F5C-1FD1-4955-BFFA-0CB017A9CF0BQ43268895-257DC6AE-FA98-4229-8225-1C2A6F69EE93Q45942815-6EC7F49F-D829-47B3-BB27-72E77E57EDE0Q50984731-5882BA4A-78F0-4C3D-BFF3-B5F8F5E7A9B6Q51134013-A4A07A99-18E1-47EC-A929-2A5516224592
P2860
Equal proportion of adult male and female homozygous for the 677C ? T mutation in the methylenetetrahydrofolate reductase polymorphism
description
im Januar 2005 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у 2005
@uk
name
Equal proportion of adult male ...... ofolate reductase polymorphism
@en
Equal proportion of adult male ...... ofolate reductase polymorphism
@nl
type
label
Equal proportion of adult male ...... ofolate reductase polymorphism
@en
Equal proportion of adult male ...... ofolate reductase polymorphism
@nl
prefLabel
Equal proportion of adult male ...... ofolate reductase polymorphism
@en
Equal proportion of adult male ...... ofolate reductase polymorphism
@nl
P2093
P2860
P356
P1476
Equal proportion of adult male ...... ofolate reductase polymorphism
@en
P2093
Arne Lund Jorgensen
Arno G. Motulsky
Cheryl A.M. Anderson
Dale McLerran
Samir Deeb
Shirley A.A. Beresford
P2860
P356
10.1002/AJMG.A.30391
P407
P577
2005-01-01T00:00:00Z